ASCO: Updated Analyses Confirm Safety and Efficacy of Ra-223 in CRPC

Further analyses of data subsets from the ALSYMPCA study of the alpha particle-emitting isotope Ra-223 (Xofigo) were presented at ASCO, providing additional evidence of efficacy and safety of the recently FDA approved therapeutic agent.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news